Journal News

A target to prevent kidney injury by chemotherapy

Aswathy Rai
Sept. 27, 2022

Cis-diamminedichloroplatinum II, commonly known as cisplatin, is a chemotherapeutic agent used to treat various cancers. However, cisplatin-induced acute kidney injury, or AKI, can result from the uptake, metabolism and accumulation of cisplatin by proximal tubular epithelial cells in the kidney. The accumulation leads to apoptosis, vascular damage, necrosis, oxidative and endoplasmic reticulum stress, and inflammation. 

Cisplatin, a platinum compound used as a chemotherapy drug, can have severe side effects.
Larry Ostby/Wikimedia Commons
Cisplatin, a platinum compound used as a chemotherapy drug, can have severe
side effects.

Leah Siskind at the University of Louisville has been researching mechanisms to protect the kidney from off-target harmful effects of chemotherapeutics such as cisplatin. Her long-term research goal is to extend the life span of patients while preserving their quality of life. 

“Many people don’t realize that the side effects of chemotherapy are not limited to hair loss, diarrhea and nausea,” Siskind said. “Kidney injury is one of the significant dose-limiting side effects of cisplatin. Therefore, we cannot use cisplatin at the dose we should use it at because it is so bad for the kidney. And even when we use cisplatin at the safe levels, 30% of all patients develop nephrotoxicity.”

Ceramide, sphingosine and sphingosine 1-phosphate, or S1P, are bioactive sphingolipids responsible for various forms of cell death and destruction. Ceramidases, or CDases, are enzymes that maintain the dynamic balance in concentrations of ceramide and sphingosine in the cell. Ceramidases cleave the fatty acid from ceramide to produce sphingosine, which eventually is metabolized to S1P or salvaged to form ceramide again. 

CDases fall into three broad categories — acidic, neutral and alkaline — based on the optimal pH for catalytic activity. Neutral ceramidases, or nCDases, function at a neutral pH, convert ceramide to sphingosine, and regulate the delicate balance between cell death and autophagy.

In a recent article in the Journal of Lipid Research, Siskind and a team of researchers reported that genetically altering mice to remove nCDase protected against cisplatin-induced AKI by reducing the recruitment of inflammatory cells, apoptosis, endoplasmic reticulum stress and increase in autophagy.

Nephrotoxic injury from acute tubular necrosis causes AKI. When the nCDase−/− mice were treated with cisplatin, mRNA levels in several inflammatory cytokines were reduced and the kidney tissue showed less damage from tubular necrosis, less loss of brush border and less tubular cast formation than in unaltered mice.

In AKI, loss of renal function is associated with increased blood urea nitrogen and serum creatinine. The levels of these chemicals were reduced significantly in cisplatin-treated nCDase−/− mice compared to cisplatin-treated mice with normal nCDase levels.

Using TUNEL staining, the authors showed that cisplatin-treated nCDase−/− mice were protected from apoptosis and cellular proliferation compared to mice with normal nCDase levels. 

“Neutral ceramidase is a great target because it seems to be very protective for kidneys when inhibited or knocked out,” Siskind said.

Previous studies from collaborator Yusuf Hannun’s lab, which elucidated the crystal structure for neutral ceramidase, showed that inhibiting nCDase can slow or stop progression of certain cancers, she added.

“The next step is to find a good inhibitor, but it’s been elusive.” 

Siskind and her collaborators will continue their work to identify mechanisms that protect the kidneys from chemotherapeutics and to find promising inhibitors of nCDase.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Aswathy Rai

Aswathy N. Rai is an assistant teaching professor and undergraduate coordinator at Mississippi State University's department of biochemistry, molecular biology, entomology and plant pathology. She is an ASBMB Today volunteer contributor.

Related articles

From the journals: JLR
Carmen Morcelle
From the journals: JLR
Latavia Hill
From the journals: March 2019
John Arnst, Courtney Chandler, Isha Dey & Catherine Goodman
From the journals: JLR
Swarnali Roy

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.